Long-Term Evaluation of the Treatment of Meni�re�s Disease with Betahistine HCl

Bertrand, Robert A.

doi:10.1159/000406747

Cited by 11 publications

(9 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The therapeutic effect of betahistine, as well its safety, has been shown in many controlled clinical studies in vertigo patients [10,11,12,13,14,15,16].…”

Section: Introductionmentioning

confidence: 99%

Betahistine dihydrochloride in the treatment of peripheral vestibular vertigo

Mira

Guidetti

Ghilardi

et al. 2003

Eur Arch Otorhinolaryngol

View full text Add to dashboard Cite

The present study compares the efficacy and safety of betahistine dihydrochloride to that of a placebo in recurrent vertigo resulting from Meniere's disease (MD) or in paroxysmal positional vertigo (PPV) of probable vascular origin. The design was double-blind, multicentre and parallel-group randomised. Eleven Italian cen-tres enrolled 144 patients: 75 of the patients were treated with betahistine (41 MD/34 PPV) and 69 with placebos (40 MD/29 PPV). The betahistine dosage was 16 mg twice per day for 3 months. Compared to the placebo, betahistine had a significant effect on the frequency, intensity and duration of vertigo attacks. Associated symptoms and the quality of life also were significantly improved by betahistine. Both the physician's judgement and the patient's opinion on the efficacy and acceptability of the treatment were in agreement as to the superiority of betahistine. The effective and safe profile of betahistine in the treatment of vertigo due to peripheral vestibular disorders was confirmed.

show abstract

“…The therapeutic effect of betahistine, as well its safety, has been shown in many controlled clinical studies in vertigo patients [10,11,12,13,14,15,16].…”

Section: Introductionmentioning

confidence: 99%

Betahistine dihydrochloride in the treatment of peripheral vestibular vertigo

Mira

Guidetti

Ghilardi

et al. 2003

Eur Arch Otorhinolaryngol

View full text Add to dashboard Cite

show abstract

“…[22][23] The therapeutic effect of betahistine and its safety have been shown in many controlled studies. 24,25 Despite the low number of patients reported in this paper, betahistine showed excellent therapeutic results; at the 3-mo control, spells were reduced by 69% and duration decreased by 52%. After 6 mo, spells had decreased by 72% and duration by 76%.…”

Section: Discussionmentioning

confidence: 75%

“…Results are no different from those reported in other papers. [25][26] LLLT targeting the inner ear has been discussed as a therapeutic procedure for cochlear dysfunctions such as chronic cochlear tinnitus or sensorineural hearing loss. Earlier studies have demonstrated dose-dependent biological and physiological effects of LLLT, such as enhanced recovery of peripheral nerve injuries, which could be of therapeutic interest in cochlear dysfunction.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of Low-Level Laser Therapy in Ménière's Disease: A Pilot Study of 10 Patients

Teggi

Bellini

Fabiano

et al. 2008

Photomedicine and Laser Surgery

View full text Add to dashboard Cite

show abstract

“…HA has been largely used for treatment of vertigo and disturbances of the inner ear assumed to be of vascular origin (Fischer, 1991). Betahistine is a structural analog of HA that is effective also in vestibular syndromes unrelated to vascular insufficiency like peripheral vestibular disorders (Canty and Valentine, 1981; Oosterveld, 1984) and Menière’s disease (Frew and Menon, 1976; Bertrand, 1982). We previously showed that behavioral recovery after UVN in our cat model was strongly accelerated by betahistine (Tighilet et al, 1995).…”

Section: Discussionmentioning

confidence: 99%

Plasticity of the histamine H3 receptors after acute vestibular lesion in the adult cat

Tighilet¹,

Mourre²,

Lacour³

2014

Front. Integr. Neurosci.

View full text Add to dashboard Cite

After unilateral vestibular neurectomy (UVN) many molecular and neurochemical mechanisms underlie the neurophysiological reorganizations occurring in the vestibular nuclei (VN) complex, as well as the behavioral recovery process. As a key regulator, the histaminergic system appears to be a likely candidate because drugs interfering with histamine (HA) neurotransmission facilitate behavioral recovery after vestibular lesion. This study aimed at analyzing the post-lesion changes of the histaminergic system by quantifying binding to histamine H3 receptors (H3R; mediating namely histamine autoinhibition) using a histamine H3 receptor agonist ([3H]N-α-methylhistamine). Experiments were done in brain sections of control cats (N = 6) and cats submitted to UVN and killed 1 (N = 6) or 3 (N = 6) weeks after the lesion. UVN induced a bilateral decrease in binding density of the agonist [3H]N-α-methylhistamine to H3R in the tuberomammillary nuclei (TMN) at 1 week post-lesion, with a predominant down-regulation in the ipsilateral TMN. The bilateral decrease remained at the 3 weeks survival time and became symmetric. Concerning brainstem structures, binding density in the VN, the prepositus hypoglossi, the subdivisions of the inferior olive decreased unilaterally on the ipsilateral side at 1 week and bilaterally 3 weeks after UVN. Similar changes were observed in the subdivisions of the solitary nucleus only 1 week after the lesion. These findings indicate vestibular lesion induces plasticity of the histamine H3R, which could contribute to vestibular function recovery.

show abstract

Long-Term Evaluation of the Treatment of Meni�re�s Disease with Betahistine HCl

Cited by 11 publications

References 0 publications

Betahistine dihydrochloride in the treatment of peripheral vestibular vertigo

Betahistine dihydrochloride in the treatment of peripheral vestibular vertigo

Efficacy of Low-Level Laser Therapy in Ménière's Disease: A Pilot Study of 10 Patients

Plasticity of the histamine H3 receptors after acute vestibular lesion in the adult cat

Contact Info

Product

Resources

About